In a major development, the Top Vaccine manufacturer Serum Institute of India (SSI) said that it has commenced manufacturing Covovax, a Covid-19 vaccine developed by Novavax in it's plant in Pune. A message tweeted by the SSI director Poonawalla reads: "A new milestone has been reached; this week we began our first batch of Covovax (a COVID-19 vaccine developed by @Novavax) at our facility, here in Pune,"

Excited to witness the first batch of Covovax (developed by @Novavax) being manufactured this week at our facility in Pune. The vaccine has great potential to protect our future generations below the age of 18. Trials are ongoing. Well done team @seruminstindia," the tweet adds.

In March this year, he had said that the clinical trials of the Covovax vaccine have begun in India and the company hopes to launch it by September this year. In August 2020, American vaccine company Novavax Inc had announced a licence agreement with SII for the development and commercialisation of NVX-CoV2373, its COVID-19 vaccine candidate, in low and middle-income countries and India.

Health ministry statement on the second wave of corona

776 doctors lose their lives in second corona wave, the highest number of deaths is from Bihar

Corona cases suddenly rise in Israel, mandatory to wear masks at home